Contrasting 180 Life Sciences (NASDAQ:ATNF) and Immunic (NASDAQ:IMUX)

Immunic (NASDAQ:IMUX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, earnings, dividends, profitability, valuation and risk.

Institutional and Insider Ownership

51.8% of Immunic shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 3.0% of Immunic shares are held by insiders. Comparatively, 0.2% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Immunic and 180 Life Sciences”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61 million	($1.23)	-0.89
180 Life Sciences	N/A	N/A	-$19.93 million	N/A	N/A

Volatility and Risk

Immunic has a beta of 1.89, suggesting that its stock price is 89% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Immunic and 180 Life Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0	0	7	2	3.22
180 Life Sciences	0	0	0	0	0.00

Immunic currently has a consensus target price of $12.67, indicating a potential upside of 1,062.08%. Given Immunic’s stronger consensus rating and higher possible upside, equities analysts clearly believe Immunic is more favorable than 180 Life Sciences.

Profitability

This table compares Immunic and 180 Life Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
180 Life Sciences	N/A	-558.93%	-54.10%

Summary

Immunic beats 180 Life Sciences on 8 of the 10 factors compared between the two stocks.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.